Clinical Study | Office of Clinical Research

Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy

Posted Date: May 17, 2019

Investigator: David Steward
Specialties: Oncology, Otolaryngology, Thyroid Cancer
Type of Study: Drug

The purpose of this study is to evaluate the effect of cabozantinib compared with a placebo in treating patients whose disease has progressed after receiving prior treatment with drugs that inhibit growth of tumor blood vessel (VEGFR-targeted therapy) for their thyroid cancer.

Criteria:

Null

Keywords:

Thyroid Cancer, Cabozantinib

For More Information:

Becky
NULL
gibsonrk@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List